HomeCompareMPCFF vs ABBV

MPCFF vs ABBV: Dividend Comparison 2026

MPCFF yields 4000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MPCFF wins by $3743811617672466.50M in total portfolio value
10 years
MPCFF
MPCFF
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
12.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3743811617672466.50M
Annual income
$3,687,468,229,378,192,700,000.00
Full MPCFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — MPCFF vs ABBV

📍 MPCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPCFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPCFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPCFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPCFF
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,134,347,994,971,464,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, MPCFF beats the other by $3,134,347,994,971,464,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPCFF + ABBV for your $10,000?

MPCFF: 50%ABBV: 50%
100% ABBV50/50100% MPCFF
Portfolio after 10yr
$1871905808836233.25M
Annual income
$1,843,734,114,689,096,400,000.00/yr
Blended yield
98.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MPCFF
No analyst data
Altman Z
0.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPCFF buys
0
ABBV buys
0
No recent congressional trades found for MPCFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPCFFABBV
Forward yield4000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.4%40.6%
Portfolio after 10y$3743811617672466.50M$104.7K
Annual income after 10y$3,687,468,229,378,192,700,000.00$25,725.73
Total dividends collected$3740070324761762.00M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MPCFF vs ABBV ($10,000, DRIP)

YearMPCFF PortfolioMPCFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$460,300$449,600.00$11,559$438.51+$448.7KMPCFF
2$22,232,034$21,739,513.00$13,494$640.86+$22.22MMPCFF
3$1,126,775,718$1,102,987,441.51$15,951$945.97+$1126.76MMPCFF
4$59,929,075,693$58,723,425,674.57$19,152$1,413.89+$59929.06MMPCFF
5$3,345,031,836,956$3,280,907,725,965.03$23,443$2,146.38+$3345031.81MMPCFF
6$195,950,017,215,147$192,370,833,149,603.38$29,391$3,321.96+$195950017.19MMPCFF
7$12,047,352,351,791,656$11,837,685,833,371,448.00$37,948$5,265.87+$12047352351.75MMPCFF
8$777,422,635,368,021,600$764,531,968,351,604,600.00$50,795$8,596.74+$777422635367.97MMPCFF
9$52,657,372,237,638,710,000$51,825,530,017,794,930,000.00$71,034$14,549.41+$52657372237638.64MMPCFF
10$3,743,811,617,672,466,500,000$3,687,468,229,378,192,700,000.00$104,715$25,725.73+$3743811617672466.50MMPCFF

MPCFF vs ABBV: Complete Analysis 2026

MPCFFStock

Metro Pacific Investments Corporation, an investment holding company, develops infrastructure assets through its investments in water, toll roads, power generation and distribution, healthcare services, and light rail and logistics in the Philippines. It operates through Power, Toll Operations, Water, Rail, and Others segments. The company provides water and sewerage services through a network of pipelines, pumping stations, and mini-boosters in the West Service Area of Metro Manila; and operates a network of 7,748 kilometers of pipelines. It constructs, operates, and maintains the North Luzon Expressway (NLEX), the NLEX- South Luzon Expressway connector road, and the Cebu-Cordova Link Expressway; operates, manages, and maintains the Subic-Clark-Tarlac Expressway; operates and maintains the Manila-Cavite Toll Expressway; designs, finances, constructs, operates, and maintains the 44.6-km Cavite Laguna Expressway. The company also constructs, operates, and maintains electric distribution systems in 36 cities and 75 municipalities serving 7.4 million customers; owns and operates power plants; and operates and manages 18 hospitals and 6 cancer centers. In addition, it operates and maintains the light rail transit line; designs, develops, and markets real estate properties; and provides electromechanical engineering, construction, e-transaction and bills collection, telecommunications, rail-related operations and maintenance, insurance and re-insurance, and consulting and related manpower services; as well as e-business development, power distribution management, energy systems management, harnessing renewable energy, and electric vehicle and charging infrastructure solutions; and electronic toll collection, facilities management, waste management services. Further, the company engages in the rental and leasing of residential properties, trading, and port management activities. The company was founded in 1986 and is headquartered in Pasig, the Philippines.

Full MPCFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MPCFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPCFF vs SCHDMPCFF vs JEPIMPCFF vs OMPCFF vs KOMPCFF vs MAINMPCFF vs JNJMPCFF vs MRKMPCFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.